Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02239614 · ClinicalTrials.gov registry record · Phase 1
TDENV PIV and LAV Dengue Prime-boost Strategy
A Phase 1 study of Dengue, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT02239614 is a Phase 1 study of Dengue that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 80 participants, below the 3,972-participant average among 9 other Dengue trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02239614, a Phase 1 study of Dengue, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans will be evaluated in this study. A prime-boost study of tetravalent dengue virus purified inactivated vaccine (TDENV-PIV) with alum and tetravalent dengue live attenuated virus (TDENV-LAV) vaccine Formulation 17 (F17) will gather data to help better understand the human immune response to dengue vaccination and infection.
Conditions Studied
Interventions
- BIOLOGICAL TDENV-LAV
- BIOLOGICAL TDENV-PIV 4 µg + alum adjuvant
Study Locations (1)
Maryland
- Clinical Trials Center, Walter Reed Army Institute of Research (CTC, WRAIR) - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-02-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02239614
The ClinicalTrials.gov registry entry for NCT02239614 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,972-participant average among 9 other Dengue trials with a reported enrollment target (98% lower). The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dengue appearing as the primary indexed condition, and to 2 interventions - of which TDENV-LAV is the first listed.
NCT02239614 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02239614 about?
NCT02239614 is a clinical study titled "TDENV PIV and LAV Dengue Prime-boost Strategy". The potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans will be evaluated in this study. A prime-boost study of tetravalent dengue virus purified inactivated vaccine (TDENV-PIV) with alum and tetravalent dengue liv...
What is the current status of trial NCT02239614?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2014-12. Estimated completion is 2017-02-17.
What conditions does trial NCT02239614 study?
This clinical trial studies the following conditions: Dengue.
What interventions are being tested in trial NCT02239614?
The interventions under investigation include: TDENV-LAV (BIOLOGICAL), TDENV-PIV 4 µg + alum adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT02239614?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02239614 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dengue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
COMPLETED · Phase 1
-
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
COMPLETED · Phase 1
-
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
COMPLETED · Phase 1
-
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
COMPLETED · Phase 1
-
Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
COMPLETED · Phase 1
-
Tetravalent Chimeric Dengue Vaccine Trial
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.